ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för KP1019. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

28 träffar

Bibliografisk träff 2020-06-01

Proteomic analysis of the S. cerevisiae response to the anticancer ruthenium complex KP1019.

Stultz LK, Hunsucker A, Middleton S, Grovenstein E, O'Leary J, Blatt E, Miller M, Mobley J, Hanson PK.

Metallomics · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1039/d0mt00008f

Bibliografisk träff 2018-02-24

Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA<sup>Phe</sup>.

Dwyer BG, Johnson E, Cazares E, McFarlane Holman KL, Kirk SR.

J Inorg Biochem · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1016/j.jinorgbio.2018.02.019

Bibliografisk träff 2018-02-01

The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years?

Alessio E, Messori L.

Met Ions Life Sci · historical article; research support, non-u.s. gov't; review; journal article · DOI 10.1515/9783110470734-011

Bibliografisk träff 2018-01-01

Studies of KP46 and KP1019 and the Hydrolysis Product of KP1019 in Lipiodol Emulsions: Preparation and Initial Characterizations as Potential Theragnostic Agents.

Pashkunova-Martic I, Losantos BC, Kandler N, Keppler B.

Curr Drug Deliv · journal article · DOI 10.2174/1567201813666161220153702

Bibliografisk träff 2016-08-01

Comparison of KP1019 and NAMI-A in tumour-mimetic environments.

Gransbury GK, Kappen P, Glover CJ, Hughes JN, Levina A, Lay PA, Musgrave IF, Harris HH.

Metallomics · journal article · DOI 10.1039/c6mt00145a

Bibliografisk träff 2016-06-07

X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.

Bijelic A, Theiner S, Keppler BK, Rompel A.

J Med Chem · research-article; journal article · DOI 10.1021/acs.jmedchem.6b00600

Bibliografisk träff 2016-05-04

CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.

Chang SW, Lewis AR, Prosser KE, Thompson JR, Gladkikh M, Bally MB, Warren JJ, Walsby CJ.

Inorg Chem · journal article · DOI 10.1021/acs.inorgchem.6b00359

Bibliografisk träff 2016-03-03

Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action.

Bytzek AK, Koellensperger G, Keppler BK, G Hartinger C.

J Inorg Biochem · journal article · DOI 10.1016/j.jinorgbio.2016.02.037

Bibliografisk träff 2014-11-12

Modulation of the Aβ peptide aggregation pathway by KP1019 limits Aβ-associated neurotoxicity.

Jones MR, Mu C, Wang MC, Webb MI, Walsby CJ, Storr T.

Metallomics · research support, non-u.s. gov't; journal article · DOI 10.1039/c4mt00252k

Bibliografisk träff 2014-06-11

Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).

Sadafi FZ, Massai L, Bartolommei G, Moncelli MR, Messori L, Tadini-Buoninsegni F.

ChemMedChem · research support, non-u.s. gov't; journal article · DOI 10.1002/cmdc.201402128

Bibliografisk träff 2014-05-02

Anti-cancer drug KP1019 induces Hog1 phosphorylation and protein ubiquitylation in Saccharomyces cerevisiae.

Singh V, Azad GK, Azad GK, Reddy M A, Baranwal S, Tomar RS.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2014.04.032

Bibliografisk träff 2014-05-01

Nanoformulation improves activity of the (pre)clinical anticancer ruthenium complex KP1019.

Heffeter P, Riabtseva A, Senkiv Y, Kowol CR, Körner W, Jungwith U, Mitina N, Keppler BK, Konstantinova T, Yanchuk I, Stoika R, Zaichenko A, Berger W.

J Biomed Nanotechnol · research support, non-u.s. gov't; journal article · DOI 10.1166/jbn.2014.1763

Bibliografisk träff 2014-02-20

Anti-cancer drug KP1019 modulates epigenetics and induces DNA damage response in Saccharomyces cerevisiae.

Singh V, Azad GK, Azad GK, Mandal P, Reddy MA, Tomar RS.

FEBS Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.febslet.2014.02.017

Bibliografisk träff 2013-10-29

Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation.

Fischer B, Heffeter P, Kryeziu K, Gille L, Meier SM, Berger W, Kowol CR, Keppler BK.

Dalton Trans · research support, non-u.s. gov't; journal article · DOI 10.1039/c3dt52388h

Bibliografisk träff 2013-09-20

EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.

Webb MI, Walsby CJ.

Metallomics · research support, non-u.s. gov't; journal article · DOI 10.1039/c3mt00090g

Bibliografisk träff 2012-10-22

The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae.

Stevens SK, Strehle AP, Miller RL, Gammons SH, Hoffman KJ, McCarty JT, Miller ME, Stultz LK, Hanson PK.

Mol Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1124/mol.112.079657

Bibliografisk träff 2012-10-18

Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.

Dömötör O, Hartinger CG, Bytzek AK, Kiss T, Keppler BK, Enyedy EA.

J Biol Inorg Chem · research support, non-u.s. gov't; journal article · DOI 10.1007/s00775-012-0944-6

Bibliografisk träff 2012-08-20

Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells.

Aitken JB, Antony S, Weekley CM, Lai B, Spiccia L, Harris HH.

Metallomics · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1039/c2mt20072d

Bibliografisk träff 2011-06-26

Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.

Bartel C, Egger AE, Jakupec MA, Heffeter P, Galanski MS, Berger W, Keppler BK.

J Biol Inorg Chem · research support, non-u.s. gov't; journal article · DOI 10.1007/s00775-011-0809-4

Bibliografisk träff 2010-03-11

Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.

Heffeter P, Böck K, Atil B, Reza Hoda MA, Körner W, Bartel C, Jungwirth U, Keppler BK, Micksche M, Berger W, Koellensperger G.

J Biol Inorg Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s00775-010-0642-1

Bibliografisk träff 2009-09-17

Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion.

Bergamo A, Masi A, Jakupec MA, Keppler BK, Sava G.

Met Based Drugs · research-article; journal article · DOI 10.1155/2009/681270

Bibliografisk träff 2009-08-26

Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.

Cetinbas N, Webb MI, Dubland JA, Walsby CJ.

J Biol Inorg Chem · research support, non-u.s. gov't; journal article · DOI 10.1007/s00775-009-0578-5

Bibliografisk träff 2009-02-01

Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.

Lentz F, Drescher A, Lindauer A, Henke M, Hilger RA, Hartinger CG, Scheulen ME, Dittrich C, Keppler BK, Jaehde U, Central European Society for Anticancer Drug Research-EWIV.

Anticancer Drugs · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1097/cad.0b013e328322fbc5

Bibliografisk träff 2009-01-01

Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors.

Henke MM, Richly H, Drescher A, Grubert M, Alex D, Thyssen D, Jaehde U, Scheulen ME, Hilger RA.

Int J Clin Pharmacol Ther · journal article · DOI 10.5414/cpp47058

Bibliografisk träff 2008-10-01

KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.

Hartinger CG, Jakupec MA, Zorbas-Seifried S, Groessl M, Egger A, Berger W, Zorbas H, Dyson PJ, Keppler BK.

Chem Biodivers · research support, non-u.s. gov't; review; journal article · DOI 10.1002/cbdv.200890195

Bibliografisk träff 2005-08-01

The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells.

Kapitza S, Jakupec MA, Uhl M, Keppler BK, Marian B.

Cancer Lett · journal article · DOI 10.1016/j.canlet.2005.01.002

Bibliografisk träff 2005-06-01

Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis.

Timerbaev AR, Rudnev AV, Semenova O, Hartinger CG, Keppler BK.

Anal Biochem · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.ab.2005.03.020

Bibliografisk träff 2004-08-26

Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).

Heffeter P, Pongratz M, Steiner E, Chiba P, Jakupec MA, Elbling L, Marian B, Körner W, Sevelda F, Micksche M, Keppler BK, Berger W.

J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.104.073395